NCT06458036View on ClinicalTrials.gov

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

November 1, 2030

Study Completion Date

November 1, 2031

Conditions
Differentiated Thyroid CancerPediatric CancerCancerCancer, Thyroid
Interventions
DRUG

Selpercatinib Monotherapy

Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.

RADIATION

131I Therapy

Patients will receive 131I therapy after 6 months of selpercatinib.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

United States Department of Defense

FED

lead

Children's Hospital of Philadelphia

OTHER